Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests local injections for stubborn HS lesions

NCT ID NCT07261072

Disease control Sponsor: Peking Union Medical College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares injecting secukinumab directly into skin lesions versus standard under-the-skin injections for people with localized hidradenitis suppurativa (HS). The goal is to see if local delivery works better and causes fewer side effects. Thirty adults with HS lesions in one body area will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Secukinumab
What this could lead to
If successful, this could offer a more effective and safer way to treat localized HS lesions with secukinumab, reducing side effects.
What could go wrong
This is a small, early exploratory trial with only 30 participants, so results may not apply broadly. Local injections may not work better than standard shots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Meet international diagnostic criteria for hidradenitis suppurativa 2. Aged ≥ 18 years 3. Disease duration ≥ 6 months and resistance to conventional therapy (no significant improvement for ≥ 3 months) 4. Lesions were confined to a single anatomical area 5. Voluntarily signed the informed consent form and was able to cooperate in all visits and examinations. Exclusion Criteria: 1. Hypersensitivity to any component of secukinumab injection 2. With severe vital organ failure 3. With active infection or malignancy (malignancy within the past 5 years, except for basal or squamous cell carcinoma of the skin and cured) 4. Treatment with biologics, immunosuppressants, or systemic corticosteroids within the last 3 months 5. Pregnant, nursing, or planning conception during the study 6. Mental disorders or cognitive impairment that precludes understanding of study procedures 7. Participating in another clinical study and are at risk of an interaction between the study drugs 8. Other conditions assessed by the investigators as inappropriate for participation in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa (acne inversa) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa (acne inversa) Hidradenitis suppurativa (HS) Secukinumab

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing, Jiangsu 210042

    Nanjing, Jiangsu, 210042, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.